NCT04942964View on ClinicalTrials.gov

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

January 11, 2022

Study Completion Date

January 20, 2022

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

Bocidelpar

Oral

Trial Locations (3)

32809

Orlando Clinical Research Center, Inc, Orlando

33147

Advanced Pharma CR, LLC, Miami

78215

Texas Liver Institute, San Antonio

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04942964 - A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | Biotech Hunter | Biotech Hunter